Introduction
Ibex Medical Analytics is a Tel Aviv-based company that has built clinical-grade artificial intelligence for digital pathology since 2016. Co-founder Joseph Mossel appears on Ibex’s leadership page as President and General Manager, U.S., following a February 18, 2026 transition in which Yair Heller, formerly chief operating officer, was appointed chief executive officer. Mossel continues on the board and leads Ibex’s expanding biopharma division and U.S. clinical growth initiatives, per Ibex’s official press release on the leadership change.
Ibex positions itself as among the most widely deployed AI pathology platforms worldwide, supporting pathologists with detection, grading, and classification across multiple cancer types on both H&E and IHC-stained slides. Deployments span Israel, Europe, and the United States — geographies with different digital pathology maturity and reimbursement rules that Ibex navigates through phased product clearance and lab partnerships rather than a single global launch playbook.
What the company does
Ibex develops AI algorithms that analyze digitized histopathology slides, supporting prostate, breast, lung, and gastric cancer workflows in clinical laboratories. Its Ibex Prostate product assists with biopsy and TURP specimen review; additional modules address other tumor types and IHC biomarker quantification. On the biopharma side, Ibex extends its platform into biomarker assessment, clinical trial optimization, and companion diagnostic development pipelines — an area Mossel focuses on following the 2026 leadership transition.
Clinical-grade validation — FDA and CE-IVDR clearances referenced in Ibex materials — separates Ibex from research-only slide classifiers that laboratories cannot deploy for sign-out support. Biopharma customers use consistent AI readouts to reduce inter-pathologist variability in trial endpoints, a problem that manually reviewed slides alone rarely solves at multi-site scale.
Ibex integrates with laboratory information systems and digital slide management workflows so pathologists review AI annotations inside familiar sign-out interfaces rather than exporting images to standalone viewers — a deployment pattern HNL Lab Medicine cited when announcing its March 2026 partnership.
Who it serves
Ibex serves hospital and health-system pathology departments, independent clinical laboratories, and pharmaceutical organizations running trials where standardized AI pathology readouts reduce variability. The March 19, 2026 partnership with HNL Lab Medicine — a multi-regional U.S. laboratory — illustrates Ibex’s push into high-volume independent lab environments where digital workflows are already established.
Company background
Ibex was founded in 2016 in Israel by Joseph Mossel and Chaim Linhart, Ph.D., who remains co-founder and chief technology officer. The company grew from research-grade pathology AI into FDA- and CE-IVDR-cleared clinical products deployed across multiple countries. Mossel served as CEO prior to the February 2026 transition, a tenure he referenced in Ibex’s press materials as a period of building global deployment before shifting focus to biopharma expansion.
Product and AI capabilities
Ibex’s core capability is computer vision applied to whole-slide images, trained on large annotated slide libraries and validated for clinical use. The company emphasizes assistive AI that supports pathologist sign-out rather than autonomous diagnosis. Its March 2026 HNL Lab Medicine deployment integrates Ibex Prostate into an established digital workflow, which HNL’s chief medical officer framed as giving pathologists advanced tools within a high-volume independent lab operating model.
Key developments
2016: Ibex founded in Tel Aviv. February 18, 2026: Yair Heller appointed CEO; Joseph Mossel moved to President and GM, U.S., leading biopharma and U.S. clinical growth (Ibex press room). March 19, 2026: HNL Lab Medicine partnership announced to deploy Ibex Prostate AI (official press release).
Ibex leadership transition reflects maturation from founder-CEO operation to specialized division leadership — a structure common among digital pathology vendors as clinical and pharma revenue lines diverge in sales motion and regulatory evidence requirements.
Why it matters
Ibex matters because digital pathology AI is transitioning from pilot algorithms to installed infrastructure in U.S. independent labs — a channel often harder to reach than academic medical centers. Mossel’s pivot to biopharma reflects a broader sector pattern: pathology AI vendors monetizing pharmaceutical trial and CDx workflows alongside clinical diagnostics. Ibex also sits alongside PathAI, Proscia, and Paige in a consolidating digital pathology market.
Laboratory directors evaluating Ibex should confirm digital slide scanner compatibility and sign-out workflow integration before piloting AI — deployment friction determines utilization more than conference demo accuracy. Ibex’s HNL partnership demonstrates intent to serve high-volume community lab economics, not only tertiary-center research programs.
Sector context
Ibex belongs in Brel’s AI in healthcare coverage under digital pathology. Readers evaluating vendor stability should compare Ibex’s clinical clearance footprint with platform vendors like Proscia that sell underlying digital infrastructure — complementary but distinct purchase decisions for laboratory directors.
Pharma pathology leaders sourcing AI for trial endpoints should ask vendors about population diversity in training data and inter-site calibration — trial failure from pathology variability is a silent cost AI vendors claim to reduce but must demonstrate in sponsor-specific validation studies.
Sources and references
Ibex HNL Lab Medicine press release (March 19, 2026) and About page leadership listing.
- Ibex — HNL Lab Medicine partnership (ibex-ai.com, March 19, 2026)
- Ibex — About / leadership (ibex-ai.com)
Reviewed July 10, 2026. Joseph Mossel is co-founder; Yair Heller is CEO. Leadership transition February 18, 2026 verified via Ibex official press room.